The University of Kansas Cancer Center-North — Kansas City, Missouri

The University of Kansas Cancer Center-North is a clinical research site located in Kansas City, Missouri, United States 64154.

Crixeo Clinical Trials Trust Score: 82/100 (GOOD). This profile has not yet been claimed by the site owner.

The University of Kansas Cancer Center-North has participated in 27 clinical trials with 9 currently active.

Therapeutic areas: Triple Negative Breast Cancer, Breast Cancer, Recurrent Squamous Cell Lung Carcinoma.

Sponsors: University of Kansas Medical Center, SWOG Cancer Research Network, Seagen, a wholly owned subsidiary of Pfizer.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Kansas City

Browse all research sites in Missouri · View every site in Kansas City

Sponsor Feasibility Report

Trust Score: 82/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for The University of Kansas Cancer Center-North?

The University of Kansas Cancer Center-North has a Crixeo Trust Score of 82/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has The University of Kansas Cancer Center-North conducted?

The University of Kansas Cancer Center-North has 27 clinical trials on record, with 9 currently active. Their work covers Triple Negative Breast Cancer, Breast Cancer, Recurrent Squamous Cell Lung Carcinoma.

Is The University of Kansas Cancer Center-North accredited by Crixeo Clinical Trials?

The University of Kansas Cancer Center-North has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about The University of Kansas Cancer Center-North?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.